1 |
Administration of rituximab and methylprednisolone |
Methylprednisolone |
[7] D00407 D00407, D00751 D00751, D00979 D00979, D02994 D02994, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
MS4A1 [2] MS4A1, NR3C1 💬 |
Hematopoietic cell lineage [2] Hematopoietic cell lineage, Neuroactive ligand-receptor interaction |
051 [1] 51 💬 |
2 |
Corticosteroid treatment (methylprednisolone or prednisolone) |
Methylprednisolone |
[14] D00407 D00407, D00472 D00472, D00751 D00751, D00979 D00979, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
064 [1] 64 💬 |
3 |
Cyclophosphamide, azathioprine,prednisone,methylprednisolone |
Azathioprine |
[11] D00238 D00238, D00287 D00287, D00407 D00407, D00473 D00473, D00751 D00751, D00979 D00979, D03033 D03033, D05000 D05000, D05001 D05001, D05002 D05002, D07760 D07760 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
042 [3] 42, 43, 45 💬 |
4 |
Infliximab, methylprednisolone, methotrexate |
Infliximab |
[9] D00142 D00142, D00407 D00407, D00751 D00751, D00979 D00979, D02115 D02115, D02598 D02598, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
DHFR [4] DHFR, DHFR2, NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [70] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 [1] 46 💬 |
5 |
Interferon-beta-1a (avonex) plus methylprednisolone |
Human interferon beta |
[7] D00407 D00407, D00751 D00751, D00979 D00979, D04554 D04554, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
IFNAR1 [3] IFNAR1, IFNAR2, NR3C1 💬 |
Coronavirus disease - COVID-19 [19] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
013 [1] 13 💬 |
6 |
Intravenous (i.v.) methylprednisolone 1000 mg, total 9 |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
222 [1] 222 💬 |
7 |
Intravenous methylprednisolone |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [2] 13, 145 💬 |
8 |
Iv methylprednisolone |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
9 |
Iv methylprednisolone (steroids) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
10 |
Megadose oral methylprednisolone |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
11 |
Methotrexate + methylprednisolone |
Methotrexate |
[8] D00142 D00142, D00407 D00407, D00751 D00751, D00979 D00979, D02115 D02115, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
DHFR [3] DHFR, DHFR2, NR3C1 💬 |
Antifolate resistance [6] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, Neuroactive ligand-receptor interaction, One carbon pool by folate |
046 [1] 46 💬 |
12 |
Methylprednisolon |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [4] 13, 14, 51, 66 💬 |
13 |
Methylprednisolon (solu-medrol) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
014 [1] 14 💬 |
14 |
Methylprednisolon-21-hydrogensuccinat, natriumsalz |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
15 |
Methylprednisolone |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [44] 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
16 |
Methylprednisolone (drug) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
17 |
Methylprednisolone (mp) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
060 [2] 60, 285 💬 |
18 |
Methylprednisolone (mp) or prednisone (pred) |
Methylprednisolone |
[7] D00407 D00407, D00473 D00473, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [1] 66 💬 |
19 |
Methylprednisolone (or other glucocorticoid) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
043 [1] 43 💬 |
20 |
Methylprednisolone (solu-medrol) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
014 [1] 14 💬 |
21 |
Methylprednisolone 1250 mg/24h x3 days |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
22 |
Methylprednisolone acetate |
Acetate |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
051 [1] 51 💬 |
23 |
Methylprednisolone bolus iv 15 mg/kg/d for 3 days. |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
084 [1] 84 💬 |
24 |
Methylprednisolone hemisuccinate |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
25 |
Methylprednisolone iv |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
26 |
Methylprednisolone mylan générique |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [1] 66 💬 |
27 |
Methylprednisolone or budesonide |
Budesonide |
[7] D00246 D00246, D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
096 [1] 96 💬 |
28 |
Methylprednisolone or prednisolone |
Methylprednisolone |
[14] D00407 D00407, D00472 D00472, D00751 D00751, D00979 D00979, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
065 [1] 65 💬 |
29 |
Methylprednisolone po |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
30 |
Methylprednisolone pulse |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [2] 66, 220 💬 |
31 |
Methylprednisolone sodium hemisuccinate |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [2] 13, 97 💬 |
32 |
Methylprednisolone sodium succinate |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [6] 13, 46, 49, 50, 51, 211 💬 |
33 |
Methylprednisolone(intravenously in the 1st-2nd-3rd month ) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [1] 66 💬 |
34 |
Methylprednisolone(intravenously in the 1st-3rd-5th month) |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [1] 66 💬 |
35 |
Methylprednisoloni natrii succinas |
- |
- |
- |
- |
050 [1] 50 💬 |
36 |
Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone |
Mesalazine |
[7] D00377 D00377, D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
37 |
Oral methylprednisolone 625 mg/24h x3 days |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [1] 13 💬 |
38 |
Prednisone (and methylprednisolone) |
Methylprednisolone |
[7] D00407 D00407, D00473 D00473, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
043 [1] 43 💬 |
39 |
Prednisone, methylprednisolone,cyclophosphamides |
Methylprednisolone |
[7] D00407 D00407, D00473 D00473, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
042 [3] 42, 43, 45 💬 |